Abivax
French tech company | Builders Republic
About
Clinical-stage pharmaceutical company developing obefazimod, an oral once-daily small molecule that enhances miR-124 expression to regulate inflammatory cytokines — targeting ulcerative colitis (positive Phase 3 results) and Crohn's disease (ENHANCE-CD trial enrolling), with a proprietary chemical library for follow-on compounds.
Key facts
- Status
- Active
- Sectors
- Healthcare & Life Sciences
- Latest stage
- Venture Round
- Founded
- 2013
- City
- PARIS
- Region
- IDF
- Tracked rounds
- 1
- Amount raised
- 49 M€ raised since 2020
Funding rounds
- Venture Round — 2022
Investors
- Deep Track Capital
- Venrock Healthcare Capital Partners